The Motley Fool

What is the Moderna share price really worth?

Coronavirus 2019-nCoV Blood Samples Medical Concept
Image source: Getty Images

Over the past year, the Moderna (NASDAQ: MRNA) share price has jumped 180%. Investors have clamoured to buy shares in the Covid-19 vaccine maker, as countries worldwide have rushed to buy its primary product. 

Unfortunately, it now looks as if the market is cooling on the business. Over the past three months, the stock has dipped by around 40%. Part of these declines can be traced back to the company’s poor third-quarter results. 

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Third-quarter results

For the period ending 30 September, the group reported earnings per share of $7.70. Revenues amounted to $5bn for the period. But the company now expects to sell fewer vaccines throughout the rest of 2021. It was initially projecting total vaccine sales for the year of $20bn. Now the target is just $18bn. 

The good news is, the organisation already has $17bn in signed advanced purchase agreements in place for 2022. This suggests sales will only drop modestly in 2022.

However, this is not guaranteed. Just because these agreements have already been signed, it does not necessarily mean customers will cough up.

Compared to a year ago, when Moderna’s vaccine was just one of three, there is now a broader range of treatments for coronavirus on the market. More potential vaccine makers are also in the process of developing and seeking regulatory approval for their treatments. 

While these challenges could impact the company’s Covid vaccine sales, I think it is important to point out that this is not a one-trick pony. 

Moderna share price potential 

In October, Moderna started recruiting patients for a Phase 3 trial of its mRNA Cytomegalovirus (CMV) Vaccine. This virus infects the majority of people at some point during their lifetime. Infections are often benign, but it poses a significant risk to pregnant mothers and recipients of donated organs.

Researchers have been trying to develop a vaccine for this virus for more than five decades. It looks as if Moderna stands a chance at being able to crack the code with its mRNA technology. Analysts estimate the potential market for such a treatment could be worth as much as $5bn a year for the company. 

The group also has a range of other treatments in its development pipeline, although it could be some time before these reach the market. 

Considering these potential treatments and sales from the Covid vaccine, Wall Street analysts believe Moderna share price is worth $300 a share. 

It looks to me as if the market is concentrating too much on Moderna’s slowing growth and is not giving any account to its growth potential.

As such, I would buy the stock for my portfolio today as a growth investment. As the rest of the market is selling, I think now could be an attractive time to snap up the shares as a long-term investment at a discounted valuation. 

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.